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ABSTRACT 
In Indonesia cervical carcinoma is the most common cancer in women and one of the leading cause 
of mortality. High risk human papillomavirus (HPV) is the major risk factor of cervical cancer. This study 
aims to know the role of IL-6, CD4+ and CD8+ T-lymphocyte for the risk of cervical carcinoma infected by 
HPV52. This study was a case control study, specimens of cervical carcinoma patients infected by HPV type-
52 as the case group and HPV type-16 or 18 as the control group. HPV genotyping used SPF10 primer and 
type specific E7 primer by LiPA. Immunohistochemistry method was used to know expression of IL-6, CD4+ 
and CD8+ T lymphocyte. Pearson’s 2 test was applied with statistical significance was set at the 2-sided 
0.05 level. The odds ratios (OR) were calculated for the risk, with 95% confidence intervals on SPSS 16.0 for 
windows. PCR examination was performed in 185 paraffin-embedded tissue. The risk of high IL-6 
expression in cervical carcinoma infected by HPV type-52 was statistically significant 6-fold higher compare 
with cervical carcinoma infected by HPV type 16 (OR = 6.00 ; CI 95% = 1.13-31.99; p = 0.03; p < 0.05) and 
HPV type 18 (OR = 6.00 ; CI 95% = 1.13-31.99; p = 0.03; p < 0.05). The risk of low CD4+ T lymphocyte 
expression in cervical carcinoma infected by HPV type 52 was statistically significant 6-fold higher and 7.43-
fold higher respectively compare with cervical carcinoma infected by HPV type 16 (OR = 6.00 ; CI 95% = 
1.003-35.91; p = 0.04; p < 0.05) and HPV type 18 (OR = 7.43 ; CI 95% = 1.23-45.01; p = 0.02; p < 0.05). The 
risk of low CD8+ T lymphocyte expression in cervical carcinoma infected by HPV type 52 was statistically 
significant 13.5-fold higher and 11-fold higher respectively compare with cervical carcinoma infected by 
HPV type 16 (OR = 13.50 ; CI 95% = 1.42-128.26; p = 0.01; p < 0.05) and HPV type 18 (OR = 11.00 ; CI 95% = 
1.16-103.94; p = 0.02; p < 0.05). No significance different between cases and controls group in mean-age, 
parity and sexual activity (p > 0.05). In conclusion, this study found that high IL-6 expression, low CD4+ and 
CD8+ T lymphocyte expression were the risk factors of cervical carcinoma infected by HPV type 52.  
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INTRODUCTION 
Cervical cancer is the second most common 
cancer in women in developing countries. It accounts 
for 80-90% of all cancer cases.
1,2,3
 In Indonesia cervical 
carcinoma is the most common cancer in women and 
one of the leading cause of mortality. In Bali cervical 
cancer   is the second   most common after breast 
cancer, it accounts for 27.5%.
4,5,6
 Many attempts have 
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been carried out, however, many obstacle and could 
not decrease the incidence and mortality rate of 
cervical cancer were faced. High risk oncogenic human 
papilloma virus (HPV) is the major risk factor of 
cervical cancer. It can be detected in about 90% of all 
cervical cancers.
5,7,8
 The two predominant high-risk 
HPV types are HPV-16 and 18 associated with more 
than 90% of cervical cancers worldwide.
5,8,9  
In Bali 
HPV type-52 is the most common type found in 
cervical cancer patients, account for 18%.
10
 The main 
pathogenesis of cervical carcinoma infected by HPV 
type-16 and 18 have been well established and widely 
accepted worldwide through tumor suppressor gene 
p53 and pRb.
  
Further study is needed to know the 
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pathogenesis of cervical carcinoma infected by other 
high risk HPV. 
8,11,12  
 The aim of this study was to know 
the role of immunologic factor, especially IL-6, CD4
+ 
T-
lymphocyte and CD8
+
 T- lymphocyte for the risk of 
cervical carcinoma infected by HPV type-52, because 
HPV type-52 is the most common type in Bali. The 
results of this study were expected to be used for new 
input in pathogenesis of cervical cancer infected by 
HPV type-52, for early diagnosis and as predictor 
factors.  
 
MATERIAL AND METHODS 
Specimen collection and histopathological diagnosis 
This study was a case control study. The sample 
consisted of biopsy or operation specimens of cervical 
carcinoma patients infected by HPV type-52 as the 
case group and biopsy or operation specimens of 
cervical carcinoma patients infected by HPV type-16 or 
18 as the control group. The study was conducted 
during the years 2011-2012 at Department of 
Obstetrics and Gynecology Faculty of Medicine 
Udayana University/Sanglah Hospital Denpasar for the 
biopsy or cervical operation. And then, these 
specimens were processed at Department of 
Anatomical Pathology Faculty of Medicine Udayana 
University/Sanglah Hospital Denpasar for 
histopathology diagnosis.  
 
HPV DNA detection and typing 
The paraffin-embedded tissue which have been 
diagnosed as cervical carcinoma were sent for 
detection and genotyping of HPV DNA by PCR-based 
methods at Department of Pathology, Leiden 
University Medical Centre, the Netherland and 
Molecular Biology Unit, Faculty of Medicine, Udayana 
University. HPV DNA was detected in 2 steps. In the 
first step, the SPF10 primer at several dilution were 
used to amplified the DNA. In the second step, the 
positive products was performed using specific probes 
type-specific E7 primer by LiPA which could detected 
25 HPV types to know the evidence of HPV type 52, 16 
and 18.  
 
Immunohistochemistry examination 
Ten specimens with HPV type 52 positive were 
used as cases. The specimen of HPV type 16 or 18 
positive, consist of 20 specimens each as controls. 
Immunohistochemistry examination was carried out 
to all of these 50 specimens for examination of IL-6, 
CD4
+ 
T-lymphocyte and CD8
+
 T-lymphocyte expression 
at Department of Anatomical Pathology Faculty of 
Medicine Gajah Mada University/ Dr. Sardjito Hospital 
Yogyakarta. 
 
Statistical analysis 
The results of this study was analyzed on SPSS 
16.0 for windows, i.e. Shapiro-Wilk test for normality 
of data, Levene’s test for homogeneity, logistic 
regression for ratio odd (RO), and Pearson’s chi-square 
test for significance. Statistical significance for these 
tests was set at the 2-sided 0.05 level with 95% 
confidence intervals (CIs). 
 
RESULTS 
The case group in this study consist of 10 
specimens of cervical carcinoma infected by HPV type-
52, the control group consist of 20 specimens of 
cervical carcinoma infected by HPV type 16 and 20 
specimens of cervical carcinoma infected by HPV type 
18. Age, parity and sexual activity were controlled by 
analysis. The results of this study were displayed in 
Table 1-3 and Figure 1-4. 
Table 1 
IL-6, CD4
+ 
and CD8
+
 T-lymphocyte expression in 
Cervical Carcinoma Infected by HPV Tipe-52 and 16 
 
 
HPV Type 
RO p CI 95% 
52 16 
high 6 4 6.00 0.03 1.13-31.99 
IL-6      
low 4 16    
      
high 1 12 6.00 0.04 1.00-35.91 
CD4
+ 
     
low 8 8    
      
high 1 12 13.50 0.01 1.42-128.26 
CD8
+ 
     
low 9 8    
Significant at p < 0.05 
 
The risk of high IL-6 expression in cervical carcinoma 
infected by HPV type 52 was statistically significant 6-
fold higher compare with cervical carcinoma infected 
by HPV type 16 (RO = 6.00; CI 95% = 1.13-31.99; p = 
0.03; p < 0.05). The risk of low CD4
+ 
T-lymphocyte 
expression in cervical carcinoma infected by HPV type 
52 was statistically significant 6-fold higher compare 
with cervical carcinoma infected by HPV type 16 (RO = 
6.00 ; CI 95% = 1.003-35.91; p = 0.04; p < 0.05). The 
risk of low CD8
+ 
T lymphocyte expression in cervical 
carcinoma infected by HPV type 52 was statistically 
significant 13.5-fold higher compare with cervical 
carcinoma infected by HPV type 16 (RO = 13.50 ; CI 
95% = 1.42-128.26; p = 0.01; p < 0.05). 
As can be seen from Table 2, the risk of high IL-
6 expression in cervical carcinoma infected by HPV 
type-52 was statistically significant 6-fold higher 
compare with cervical carcinoma infected by HPV type 
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18 (RO = 6.00 ; CI 95% = 1.13-31.99; p = 0.03; p < 0.05). 
The risk of low CD4
+ 
T lymphocyte expression in 
cervical carcinoma infected by HPV type 52 was 
statistically significant 7.43-fold higher compare with 
cervical carcinoma infected by HPV type 18 (OR = 7.43 
; CI 95% = 1.23-45.01; p = 0.02; p < 0.05). 
 
Table 2 
IL-6, CD4
+ 
and CD8
+
 T-lymphocyte expression in 
Cervical Carcinoma Infected by HPV Tipe-52 and 18 
 
 
HPV Type 
RO p CI 95% 
52 18 
high 6 4 6.00 0.03 1.13-31.99 
IL-6      
low 4 16    
      
high 2 13 7.43 0.02 1.23-45.01 
CD4
+ 
     
low 8 7    
      
high 1 11 11.00 0.02 1.16-103.94 
CD8
+ 
     
low 9 9    
Significant at p < 0.05 
 
The risk of low CD8
+ 
T-lymphocyte expression in 
cervical carcinoma infected by HPV type-52 was 
statistically significant 11-fold higher compare with 
cervical carcinoma infected by HPV type 18 (RO = 
11.00 ; CI 95% = 1.16-103.94; p = 0.02; p < 0.05). 
 
Table 3 
Mean-age, Parity and Sexual Activity between Case 
and Control Group 
 
Variable 
Case Control 
p 
HPV-52 HPV-16 
Age (years) 53.40±13.10 48.20±10.52 0.24 
Parity 3.40±1.35 2.80±1.11 0.23 
Sexual Activiy 2.40±3.18 23.40±2.76 0.54 
Variable 
Case Control 
p 
HPV-52 HPV-18 
Age (years) 53.40±13.10 50.80±10.24 0.69 
Parity 3.40±1.35 3.70±1.49 0.64 
Sexual Activiy 2.40±3.18 22.05±2.70 0.11 
Significant at p < 0.05 
 
No significance different between case and 
controls group in mean-age, parity and sexual activity 
(p > 0.05). 
 
Figure 1 
The product of PCR amplification on HPV DNA type-52 
Remarks: 
bp: base pair, Line 1: Standard DNA, Line 2: Positive 
control (102 bp), Line 3: Negative control, Line 4 and 
5: Positive result (102 bp), Line 6: Negative result. 
 
 
Figure 2 
The product of PCR amplification on HPV DNA type-16 
Remarks:  
bp: base pair, Line 1: Standard DNA, Line 2: Positive 
control (102 bp), Line 3: Negative control, Line 6 and 
10: Positive result (102 bp), Line 4, 5, 7, 8, 9 and 11: 
Negative results. 
 
 
Figure 3 
The product of PCR amplification on HPV DNA type-18 
Remarks: 
Bp: base pair Line 1: Standard DNA, Line 2: Positive 
control (102 bp), Line 3: Negative control, Line 4, 5, 6 
and 7: Positive result (102 bp). 
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Figure 4  
Immunohistochemistry Staining 
Remarks: 
A. Strong positive expression of IL-6 (450x) 
B. Strong positive expression of CD4
+
 T Lymphocyte 
(450x) 
C. Strong positive expression of CD8
+
 T Lymphocyte 
(450x) 
 
DISCUSSION 
A total of 185 cervical carcinoma specimens were 
examined in this study for genotyping of HPV by PCR. 
The positive HPV prevalence was 108 (58.38%). A total 
of 12 different high risk HPV were detected in 106 
(98.15%) specimens i.e type 16, 18, 33, 35, 39, 45, 51, 
52, 53, 58, 59, 66, but 2 specimens (1.85%) of 
unknown type. The three most common type were 43 
(39.8%) HPV type 16, 22 (20.4%) HPV type 18 and 11 
(10.2%) HPV type 52. Multiple infections were 12 
(11.1%). Study at Dr. Cipto Mangunkusumo Hospital, 
Jakarta in 74 cervical cancer specimen also found 
these three most common HPVs prevalence were 44% 
HPV type-16, 39% HPV type-18 dan 14% HPV type-52.
4
 
Population-base study for HPV genotyping in Bali 
found the three most common HPV type were 18% 
HPV type 52, 15% HPV type-16 dan 12% HPV type-
18.
10
  
Immunologic factor, genetic, environment and 
behavior have been implicated in development of HPV 
infection.
13
 Persistent HPV infection is require for 
disease progression because it lead to genomic 
instability and resulting in cervical cancer 
formation.
12,14,15 
Dysfunctional immune response is 
likely increase this persistence.
16
 Several studies found 
that immune responses vary by HPV type.
 17-19
  
Cytokines are pleiotropic glycoproteins for cell 
survival, proliferation and cell activation. IL-6 is one of 
cytokines that has role in both innate and adaptive 
immunity.
16,20
 In this study the risk of high IL-6 
expression in cervical carcinoma infected by HPV type-
52 was statistically significant 6-fold higher compare 
with cervical carcinoma infected by HPV type 16 (RO = 
6.00 ; CI 95% = 1.13-31.99; p = 0.03; p < 0.05) and HPV 
type 18 (RO = 6.00 ; CI 95% = 1.13-31.99; p = 0.03; p < 
0.05). IL-6 increases the regulation of vascular 
endothelial growth factor-A (VEGF-A) protein, which 
plays role in tumor angiogenesis so increase tumor 
development. IL-6 is a tumor angiogenesis 
modulator.
21,22
 IL-6 increases cells tumor invasion by 
affecting endothelial cell permeability, cause by 
decrease in endothel gap junction endothel, 
rearrangement of actin fibers, resulting in changes in 
cell shape so malignant cells easier to invasion.
23
 IL-6 
also has role as antiapoptotic through increases the 
expression of Mcl-1, the family of Bcl-2 via PI3-K/Akt 
pathway (Wei dkk., 2001a),
24
  increases tumor cell 
motility and decreases intercellular adhesion.
25,26
 
Cell-mediated immunity (CMI) especially CD4
+
 
and CD8
+ 
T lymphocytes play important role in 
adaptive immunity.
27,28
 Tumor infiltrating lymphocyte 
(TIL) in cervical carcinoma, the ability of persistence 
and progression were vary depend on HPV type.
18,29
 
HPV immunity is genotype specific.
 30
 In this study the 
risk of low CD4
+ 
T lymphocyte expression in cervical 
carcinoma infected by HPV type-52 was statistically 
significant 6-fold higher and 7.43 fold higher 
respectively compare to cervical carcinoma infected 
by HPV type16 (RO = 6.00 ; CI 95% = 1.003-35.91; p = 
0.04; p < 0.05) and HPV type 18 (RO = 7.43 ; CI 95% = 
1.23-45.01; p = 0.02; p < 0.05). The risk of low CD8
+ 
T- 
lymphocyte expression in cervical carcinoma infected 
by HPV type-52 was statistically significant 13.5 fold 
higher and 11 fold higher, respectively compare to 
cervical carcinoma infected by HPV type 16 (RO = 
13.50; CI 95% = 1.42-128.26; p = 0.01; p < 0.05) and 
HPV type 18 (RO = 11.00 ; CI 95% = 1.16-103.94; p = 
0.02; p < 0.05). The role of this immunologic factor 
may occur in various mechanisms. 
HPV may evade cellular immune responses by 
decreases expression of MHC I and II.
27
 MHC class II 
polymorphisms have positive correlation with cervical 
cancer. This polymorphisms cause genetic 
susceptibility and increase HPV infection persistence 
and evade the tumor cells from host immune 
recognition.
13,31 
Normal  formation and presentation 
of HLA-I at cell surface for normal response of T cell 
antiviral need various components of antigen 
processing machinary (APM).
32
 Genetic variation in 
APM components are also significantly correlated with 
risk of cervical carcinoma.
33
 To be full activated, T cells 
require costimulation with nonspecific molecule. 
Without this molecule T-cell may be come anergic and 
tolerant to HPV.
16
 Effective immune response also 
limited cause by late expression of protein viral that 
occur in terminal differentiation of squamous 
epithelial cells.
27
 The role of viral protein E6 and E7 
have been shown to be the main role in development 
of cervical carcinoma infected by HPV type 16 and 18 
by inactivation of tumor suppressor gene p53 and 
pRb.
8,11,12
 Cervical carcinoma infected by HPV type-52 
has different E2 disruption profile from HPV type-16. 
In HPV type 52 the disruption most common occur at 
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N-terminal region, whereas in HPV type 16 at H 
region. This E2 gene disruption pattern of HPV type 52 
could be type specific that occurred early in the course 
of infection and may be as initiators of oncogenic 
progression.
34 
   
High risk HPV infection is the major risk factor for 
developing cervical carcinoma but other minor risk 
factors or co-factors also contributes for disease 
progression, such as age, parity, sexual activity, race, 
sexually transmitted infection, multiple sexual partner, 
alcohol, smoking, contraception, low socio economic, 
etc.
10,16,35,36
 In this study no significance different 
between cases and controls group in mean-age, parity 
and sexual activity (p > 0.05). It means that this control 
variable not influence the result of IL-6, CD4
+
 and CD8
+
 
- lymphocytes expression. 
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